NCARDIA BV

Their core work

Ncardia is a Dutch biotech SME specializing in human iPSC-derived cardiomyocytes (heart cells) for drug screening, safety pharmacology, and cardiac disease modeling. They provide pharmaceutical and biotech companies with cell-based assays to test drug candidates for cardiovascular toxicity before clinical trials. Their platform enables early detection of cardiotoxic effects, reducing drug development failures and improving patient safety. Formerly known as Pluriomics, they have positioned themselves at the intersection of stem cell biology and pharmaceutical safety testing.

What they specialise in

How they've shifted over time

In their early H2020 period (2015-2018), Ncardia participated in broader technology platforms — micro-fabricated medical devices (InForMed), brain barrier research (BtRAIN), and metabolic cell analysis (METACELL-TM) — while coordinating their flagship drug screening project DeCISIoN. From 2020 onward, their focus narrowed sharply toward cardiovascular-specific applications: safety pharmacology, cardio-oncology, and personalized atrial fibrillation therapy. This trajectory shows a company that consolidated from a general iPSC cell provider into a cardiovascular safety and disease modeling specialist.

Ncardia is deepening into personalized cardiac medicine and cardio-oncology safety testing — sectors with growing regulatory demand as cancer therapies face increasing scrutiny for heart-related side effects.

How they like to work

Ncardia operates flexibly across roles — they coordinated DeCISIoN (their largest project at €3.2M), participated as a partner in three projects, and contributed as a third party in two others. With 83 unique consortium partners across 15 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators. This versatility suggests they are easy to integrate into consortia as either a technology provider or an active research partner, depending on what the project needs.

Ncardia has collaborated with 83 unique partners across 15 countries, indicating a well-connected European network particularly strong in pharmaceutical and biomedical research circles. Their Leiden base places them in the Dutch biotech corridor with easy access to both academic medical centers and pharma industry hubs.

What sets them apart

Ncardia occupies a niche that few SMEs can claim: they are both a producer of human iPSC-derived cardiac cells and an experienced partner in EU-scale drug safety research. Their progression from general cell technology toward cardiovascular-specific safety testing means they bring not just reagents but deep domain knowledge in cardiac toxicity. For consortium builders, they offer a rare combination — commercial-grade cell products with academic-level research capability in cardiac pharmacology.

Highlights from their portfolio

• DeCISIoN
  Their only coordinated project with €3.2M EC funding — a drug candidate screening platform that likely defined their core commercial offering.
• INSPIRE
  Directly targets innovation in safety pharmacology for cardiovascular assessment, aligning with growing regulatory requirements for cardiac safety testing in drug development.
• PersonalizeAF
  Represents their newest direction — personalized therapies for atrial fibrillation — signaling a move from general screening toward precision cardiac medicine.